Cochrane · systematic review · CD010497
Oral fumaric acid esters for psoriasis
Atwan, A, Ingram, JR, Abbott, R, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 14.3%Very low 7 · 50%Low 4 · 28.6%Moderate 1 · 7.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
FAE compared with placebo for psoriasis
Population: psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) FAE vs placebo | no estimate extracted | 3 studies · 418 participants | Low Downgraded: risk of bias, imprecision, indirectness, publication bias |
AEs leading to treatment discontinuation FAE vs placebo | no estimate extracted | 1 study · 27 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Quality of life (QoL) FAE vs placebo | no estimate extracted | 1 study · 175 participants | Low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Common nuisance AEs (not leading to treatment discontinuation) FAE vs placebo | RR 4.72 [2.45, 9.08] | 1 study · 99 participants | Moderate Downgraded: risk of bias, imprecision, indirectness, publication bias |
PASI 50 FAE vs placebo | RR 4.55 [2.8, 7.4] | 2 studies · 247 participants | Low Downgraded: risk of bias, imprecision, indirectness, publication bias |
PASI 75 FAE vs placebo | no estimate extracted | 2 studies · 247 participants | Low Downgraded: risk of bias, imprecision, indirectness, publication bias |
PASI 90 ‐ not measured FAE vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
FAE compared with MTX for psoriasis
Population: psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) FAE vs MTX | no estimate extracted | 1 study · 51 participants | Very low Downgraded: imprecision |
AEs leading to treatment discontinuation FAE vs MTX | RR 0.19 [0.02, 1.53] | 1 study · 51 participants | Very low Downgraded: imprecision |
Quality of life (QoL) ‐ not measured FAE vs MTX | no estimate extracted | 0 studies · 0 participants | Ungraded |
Common nuisance AEs (not leading to treatment discontinuation) FAE vs MTX | RR 0.89 [0.77, 1.03] | 1 study · 54 participants | Very low Downgraded: imprecision |
PASI 50 FAE vs MTX | RR 0.71 [0.41, 1.22] | 1 study · 51 participants | Very low Downgraded: imprecision |
PASI 75 FAE vs MTX | RR 0.8 [0.28, 2.29] | 1 study · 51 participants | Very low Downgraded: imprecision |
PASI 90 FAE vs MTX | RR 0.48 [0.05, 4.98] | 1 study · 51 participants | Very low Downgraded: imprecision |